The project aims to address two key questions:
(1) whether LINE1-targeting ASOs are effective alone or in combination with chemotherapy or ICIs in enhancing anti-tumor responses;
(2) how LINE1 inhibition remodels the tumor microenvironment over time, including effects on both exhausted T cells and nonimmune compartments such as stromal and epithelial cells.
(1) whether LINE1-targeting ASOs are effective alone or in combination with chemotherapy or ICIs in enhancing anti-tumor responses;
(2) how LINE1 inhibition remodels the tumor microenvironment over time, including effects on both exhausted T cells and nonimmune compartments such as stromal and epithelial cells.